CSL is harnessing its supply chain expertise to expand into cell and gene therapy
How CSL aims to use its facilities chops to compete as it expands into cell and gene therapy
CSL aims to leverage the logistics expertise it built through its plasma business to expand into cell and gene therapy. The company has a sickle cell disease program in Phase I and is lining up its next program in another rare disease.
The Jan. 22 opening of an expanded cell and gene therapy R&D and manufacturing facility in California marks a new chapter for CSL Ltd. (ASX:CSL), the leader in plasma-based products by total sales.
In stepping into a field fraught with manufacturing and supply chain challenges, CSL aims to compete on